Screener
Bio-Techne TECH D&A
D&A at other companies
Other financials
Where this comes from
Reported directly by Bio-Techne in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Bio-Techne’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056302
| Line item | Nine Months Ended / March 31, 2026 | Nine Months Ended / March 31, 2025 |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net earnings | $127,241 | $91,078 |
| Adjustments to reconcile net earnings to net cash provided by operating activities: | ||
| Depreciation and amortization | 73,218 | 82,792 |
| Costs recognized on sale of acquired inventory | — | 554 |
| Deferred income taxes | 8,045 | (18,825) |
| Stock-based compensation expense | 36,135 | 36,283 |
| (Gain) Loss on equity method investment | 335 | 169 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Bio-Techne's D&A?
- Bio-Techne (TECH) reported D&A of $24.17M in Q1 2026.
- How has Bio-Techne's D&A changed year-over-year?
- Bio-Techne's D&A decreased by 12.3% year-over-year, from $27.57M to $24.17M.
- What is the long-term trend for Bio-Techne's D&A?
- Over 3 years (2022 to 2025), Bio-Techne's D&A has grown at a 2.8% compound annual growth rate (CAGR), from $101.07M to $109.9M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Bio-Techne's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude